Literature DB >> 28394349

IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis.

Mohammed Eslam1, Duncan McLeod2, Kebitsaone Simon Kelaeng1, Alessandra Mangia3, Thomas Berg4, Khaled Thabet1,5, William L Irving6, Gregory J Dore7, David Sheridan8, Henning Grønbæk9, Maria Lorena Abate10, Rune Hartmann11, Elisabetta Bugianesi10, Ulrich Spengler12, Angela Rojas13, David R Booth14, Martin Weltman15, Lindsay Mollison16, Wendy Cheng17, Stephen Riordan18, Hema Mahajan2, Janett Fischer4, Jacob Nattermann12, Mark W Douglas1,19, Christopher Liddle1, Elizabeth Powell20, Manuel Romero-Gomez13, Jacob George1.   

Abstract

Genetic variation in the IFNL3-IFNL4 (interferon-λ3-interferon-λ4) region is associated with hepatic inflammation and fibrosis. Whether IFN-λ3 or IFN-λ4 protein drives this association is not known. We demonstrate that hepatic inflammation, fibrosis stage, fibrosis progression rate, hepatic infiltration of immune cells, IFN-λ3 expression, and serum sCD163 levels (a marker of activated macrophages) are greater in individuals with the IFNL3-IFNL4 risk haplotype that does not produce IFN-λ4, but produces IFN-λ3. No difference in these features was observed according to genotype at rs117648444, which encodes a substitution at position 70 of the IFN-λ4 protein and reduces IFN-λ4 activity, or between patients encoding functionally defective IFN-λ4 (IFN-λ4-Ser70) and those encoding fully active IFN-λ4-Pro70. The two proposed functional variants (rs368234815 and rs4803217) were not superior to the discovery SNP rs12979860 with respect to liver inflammation or fibrosis phenotype. IFN-λ3 rather than IFN-λ4 likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28394349     DOI: 10.1038/ng.3836

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  43 in total

1.  IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.

Authors:  Mohammed Eslam; Reynold Leung; Manuel Romero-Gomez; Alessandra Mangia; William L Irving; David Sheridan; Ulrich Spengler; Lindsay Mollison; Wendy Cheng; Elisabetta Bugianesi; Duncan McLeod; Abed M Zaitoun; Vito Attino; Diane Goeltz; Jacob Nattermann; Mark Douglas; David R Booth; Jacob George; Golo Ahlenstiel
Journal:  J Hepatol       Date:  2014-04-24       Impact factor: 25.083

2.  Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.

Authors:  Thomas R O'Brien; Ruth M Pfeiffer; Ashley Paquin; Krystle A Lang Kuhs; Sabrina Chen; Herbert L Bonkovsky; Brian R Edlin; Charles D Howell; Gregory D Kirk; Mark H Kuniholm; Timothy R Morgan; Howard D Strickler; David L Thomas; Ludmila Prokunina-Olsson
Journal:  J Hepatol       Date:  2015-07-15       Impact factor: 25.083

3.  HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.

Authors:  Emmanuel Thomas; Veronica D Gonzalez; Qisheng Li; Ankit A Modi; Weiping Chen; Mazen Noureddin; Yaron Rotman; T Jake Liang
Journal:  Gastroenterology       Date:  2012-01-13       Impact factor: 22.682

4.  IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.

Authors:  Pierre-Yves Bochud; Stéphanie Bibert; Zoltán Kutalik; Etienne Patin; Julien Guergnon; Bertrand Nalpas; Nicolas Goossens; Lorenz Kuske; Beat Müllhaupt; Tillman Gerlach; Markus H Heim; Darius Moradpour; Andreas Cerny; Raffaele Malinverni; Stephan Regenass; Guenter Dollenmaier; Hans Hirsch; Gladys Martinetti; Meri Gorgiewski; Marc Bourlière; Thierry Poynard; Ioannis Theodorou; Laurent Abel; Stanislas Pol; Jean-François Dufour; Francesco Negro
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

5.  Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes.

Authors:  Ewa Terczyńska-Dyla; Stephanie Bibert; Francois H T Duong; Ilona Krol; Sanne Jørgensen; Emilie Collinet; Zoltán Kutalik; Vincent Aubert; Andreas Cerny; Laurent Kaiser; Raffaele Malinverni; Alessandra Mangia; Darius Moradpour; Beat Müllhaupt; Francesco Negro; Rosanna Santoro; David Semela; Nasser Semmo; Markus H Heim; Pierre-Yves Bochud; Rune Hartmann
Journal:  Nat Commun       Date:  2014-12-23       Impact factor: 14.919

6.  Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus.

Authors:  Sachiyo Yoshio; Tatsuya Kanto; Shoko Kuroda; Tokuhiro Matsubara; Koyo Higashitani; Naruyasu Kakita; Hisashi Ishida; Naoki Hiramatsu; Hiroaki Nagano; Masaya Sugiyama; Kazumoto Murata; Takasuke Fukuhara; Yoshiharu Matsuura; Norio Hayashi; Masashi Mizokami; Tetsuo Takehara
Journal:  Hepatology       Date:  2013-03-14       Impact factor: 17.425

7.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

8.  Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis.

Authors:  Partha K Chandra; Feyza Gunduz; Sidhartha Hazari; Ramazan Kurt; Rajesh Panigrahi; Bret Poat; David Bruce; Ari J Cohen; Humberto E Bohorquez; Humberto E Behorquez; Ian Carmody; George Loss; Luis A Balart; Tong Wu; Srikanta Dash
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

9.  FibroGENE: A gene-based model for staging liver fibrosis.

Authors:  Mohammed Eslam; Ahmed M Hashem; Manuel Romero-Gomez; Thomas Berg; Gregory J Dore; Alessandra Mangia; Henry Lik Yuen Chan; William L Irving; David Sheridan; Maria Lorena Abate; Leon A Adams; Martin Weltman; Elisabetta Bugianesi; Ulrich Spengler; Olfat Shaker; Janett Fischer; Lindsay Mollison; Wendy Cheng; Jacob Nattermann; Stephen Riordan; Luca Miele; Kebitsaone Simon Kelaeng; Javier Ampuero; Golo Ahlenstiel; Duncan McLeod; Elizabeth Powell; Christopher Liddle; Mark W Douglas; David R Booth; Jacob George
Journal:  J Hepatol       Date:  2015-12-01       Impact factor: 25.083

10.  IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance.

Authors:  Yi-Fan Lu; David M Mauger; David B Goldstein; Thomas J Urban; Kevin M Weeks; Shelton S Bradrick
Journal:  Sci Rep       Date:  2015-11-04       Impact factor: 4.379

View more
  43 in total

1.  Liver: Deciphering the role of IFNλ subclasses in hepatic inflammation and fibrosis.

Authors:  Katrina Ray
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-10       Impact factor: 46.802

2.  SNPs rs10224002 in PRKAG2 may disturb gene expression and consequently affect hypertension.

Authors:  Xingbo Mo; Huan Zhang; Zhengyuan Zhou; Zhengbao Zhu; Xinfeng HuangFu; Tan Xu; Aili Wang; Zhirong Guo; Yonghong Zhang
Journal:  Mol Biol Rep       Date:  2019-01-28       Impact factor: 2.316

3.  The IFNL4 Gene Is a Noncanonical Interferon Gene with a Unique but Evolutionarily Conserved Regulation.

Authors:  Hao Zhou; Michelle Møhlenberg; Ewa Terczyńska-Dyla; Kasper Grønbjerg Winther; Nanna Hougaard Hansen; Johan Vad-Nielsen; Laura Laloli; Ronald Dijkman; Anders Lade Nielsen; Hans Henrik Gad; Rune Hartmann
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

4.  Interferon-λ rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population.

Authors:  Bisma Rauff; Ali Amar; Shafiq Ahmad Chudhary; Saqib Mahmood; Ghias Un Nabi Tayyab; Rumeza Hanif
Journal:  Arch Virol       Date:  2021-02-02       Impact factor: 2.574

Review 5.  What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection?

Authors:  Thomas R O'Brien; Sarah S Jackson
Journal:  J Interferon Cytokine Res       Date:  2019-06-04       Impact factor: 2.607

6.  IFNL4 haplotype, linkage disequilibrium and their influence on virological response to hepatitis C virus infection in Indian population.

Authors:  Neelanjana Roy; Chandreswar Prasad; Anand Kumar; Krishnendu Mondol; Kajal Jain; Renu Yadav; Jyotish Kumar Jha; Neeti Nadda; Subrat Kumar Acharya; Baibaswata Nayak
Journal:  Virusdisease       Date:  2019-07-24

7.  The role of genetics in hepatic fibrosis among hepatitis C virus patients.

Authors:  Heiyoung Park; Thomas R O'Brien; Barbara Rehermann
Journal:  Hepatology       Date:  2018-03-25       Impact factor: 17.425

8.  IFN-λ4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling.

Authors:  Adeola A Obajemu; Nina Rao; Kari A Dilley; Joselin M Vargas; Faruk Sheikh; Raymond P Donnelly; Reed S Shabman; Eric G Meissner; Ludmila Prokunina-Olsson; Olusegun O Onabajo
Journal:  J Immunol       Date:  2017-10-25       Impact factor: 5.422

Review 9.  The Genetic Association of IFN-λs with Human Inflammatory Disorders Remains a Conundrum.

Authors:  Sreedhar Chinnaswamy; Marek L Kowalski
Journal:  J Interferon Cytokine Res       Date:  2019-06-04       Impact factor: 2.607

Review 10.  Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology.

Authors:  Mohammed Eslam; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-10-22       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.